Merck reports € 59 Million expansion in Antibody-Drug Conjugate manufacturing

▴ Merck reports € 59 Million expansion in Antibody-Drug Conjugate manufacturing
Merck invests in immuno oncology

Merck, a leading science and technology company, today announced the € 59 million expansion of its HPAPI and ADC manufacturing capacity at its facilities near Madison, Wisconsin , USA. The investment will allow for the large-scale manufacture of increasingly potent compounds for therapies with the potential to treat cancer. Completion is scheduled for mid-2022, and about 50 full-time jobs are expected to be created from 2021.

"ADCs have seen incredible growth in the past decade, and regulatory approval in recent years demonstrates their promise as a targeted therapy," said Andrew Bulpin , director of Process Solutions, Merck's Life Science business. "With over 35 years of experience in this area, we were pioneers in the development and manufacture of biological products, conjugation processes and small molecules. This investment reinforces our commitment to working with innovators to make new treatments available to patients more quickly and efficient".

Merck 's new 6,500 m 2 office building will be one of the largest dedicated HPAPI manufacturing facilities, specifically designed to handle single digit nanogram occupational exposure limit materials. The project is an addition to the company's Madison campus , which was the first commercial ADC facility in North America designed to handle highly active materials. The new building will join the Merck campus based in St. Louis, Missouri , USA, specializing in bioconjugation for ADC, active pharmaceutical ingredients and the manufacture of excipients and adjuvants.

ADCs are an emerging class of highly specific drugs, created with the goal of destroying cancer cells while preserving healthy ones. Today there are only nine ADCs approved globally. However, the ADC industry is experiencing solid growth and is expected to reach € 13 billion in 2030 1 .

While ADCs can provide many benefits compared to other therapeutic options, they also present a unique set of challenges. Its development is complex, requiring rigorous containment infrastructure, and its structural exceptionality requires knowledge in a series of different technologies for small and large molecules, as well as analytical resources. Due to these challenges, more than 70% of ADC projects are outsourced to organizations specialized in their development and manufacture 2 .

With more than 35 years of experience in the development and manufacture of small molecules, biological products and ADC technologies, Merck offers extensive experience in clinical and commercial manufacturing. The company's comprehensive service portfolio combines the stages of drug development and production, from pre-clinical to commercial, from a single source. This consolidation helps to reduce risks and streamlines the process of obtaining therapies for patients more quickly.

Tags : #MerckNews #LatestPharmaInventionNewsSep10 #MerckNewInvestment #AntibodyDrugConjugate #MerckImmunoOncology #HPAPI #ADCManufacturing

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Surviving Against the Odds: Steven Spinale's Journey After an Ingrown Hair Turns DeadlyMarch 29, 2024
10 reasons why media research and Planning are essential in Healthcare marketingMarch 29, 2024
The Surprising Link Between Sleep and Age Perception: What You Need to KnowMarch 29, 2024
The Dark Side of Beauty: Kidney Damage from Hair Straightening TreatmentsMarch 29, 2024
The Dark Side of Beauty: Kidney Damage from Hair Straightening TreatmentsMarch 29, 2024
Avance Clinical at World Vaccine Congress to Share Latest Vaccine Clinical Trial News Including an HIV-1 StudyMarch 29, 2024
Sexual wellness superstore, Love Depot launches digital campaign to deliver every desireMarch 28, 2024
Recharge Your Life: Simple Ways to Boost Your Physical and Mental EnergyMarch 28, 2024
The Neurological Toll of Common Household Chemicals: Insights from Recent ResearchMarch 28, 2024
The Aging Puzzle: Decoding the Mechanisms of AgingMarch 28, 2024
The Double-Edged Sword of Kala-azar Treatment: Shedding Light on Eye ComplicationsMarch 28, 2024
FTCCI Launches Industry-Academia Connect to improve the employability of Engineering Graduates and address the growing demand for Talent in Emerging TechMarch 27, 2024
NTT and Olympus Begin World's First Joint Demonstration Experiment of Cloud Endoscopy SystemMarch 27, 2024
NTT and Olympus Begin World's First Joint Demonstration Experiment of Cloud Endoscopy SystemMarch 27, 2024
2nd Edition of IIFL JITO Ahimsa Run for peace & for non-violence to be held on 31st MarchMarch 27, 2024
Brij Hotels Announced 4 Million in Series A Funding March 27, 2024
Combatting Childhood Sedentariness: The Key to Preventing Premature Vascular DamageMarch 27, 2024
Crucial Findings: Unlocking Paths to Combat Ebola's DevastationMarch 27, 2024
Guarding Against Disease: The Crucial Role of Oral Hygiene in Preventive HealthcareMarch 27, 2024
Sanofi & Cipla announce exclusive distribution partnership to expand reach of CNS portfolio in IndiaMarch 26, 2024